Exagen Inc. - XGN STOCK NEWS

Exagen Inc. (XGN) reported record financial results for 2021, with total revenue at $48.3 million, up from $42 million in 2020. The testing revenue reached $47.1 million, marking a 27.8% increase year-over-year. During Q4 2021, revenue was $12.7 million, driven by record testing volumes. Despite these gains, Exagen faced a net loss of $26.9 million for the year. Noteworthy achievements included a retention rate of approximately 99% among providers and the acquisition of exclusive technology for the AVISE® RADR platform. The company expects 2022 revenue between $51 million and $53 million.

Exagen Inc. (Nasdaq: XGN) has formed a new Scientific Advisory Board (SAB) comprised of seven distinguished doctors and rheumatology experts, enhancing its capabilities in autoimmune testing solutions. This esteemed group includes industry leaders such as Stanley Cohen, MD, and Andrew Concoff, MD, among others. The SAB is expected to provide valuable insights that will contribute to the growth and development of Exagen's AVISE® RADR platform. CEO Ron Rocca expressed excitement over the board's potential to guide the company in advancing its goals.

Exagen Inc. (Nasdaq: XGN) announced its participation in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum on March 22-23, 2022. Ron Rocca, President and CEO, and Kamal Adawi, CFO, will engage in a virtual fireside chat on March 23 at 3:45 PM ET. Interested parties can access the live webcast through Exagen’s website. Exagen focuses on autoimmune testing solutions, aiming to improve care for autoimmune disease patients with its AVISE® brand testing products.

Exagen Inc. (Nasdaq: XGN) will announce its financial results for the year and fourth quarter ended December 31, 2021, on March 22, 2022, after market close. The earnings call will be hosted by key executives, including CEO Ron Rocca, CFO Kamal Adawi, and COO Mark Hazeltine, at 4:30 PM ET. Investors can access the call via phone or webcast, with a replay available until March 29, 2022. Exagen focuses on providing innovative autoimmune testing solutions aimed at improving patient care for diseases like rheumatoid arthritis and lupus.

Exagen Inc. (Nasdaq: XGN) has announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15-17, 2022. CEO Ron Rocca and CFO Kamal Adawi will engage in a virtual fireside chat on February 16 at 2:00 PM ET, accessible to conference attendees. Additionally, one-on-one meetings with investors can be scheduled through BTIG. Exagen specializes in autoimmune testing solutions, aiming to improve care for chronic autoimmune diseases with its AVISE® brand products.

Exagen Inc. (Nasdaq: XGN) has entered a research collaboration and exclusive licensing agreement with Queen Mary University of London to enhance precision medicine approaches for rheumatoid arthritis (RA). This partnership aims to develop patent-pending assays that utilize RNA expression signatures to improve therapeutic selection for RA patients. With approximately two million individuals affected by RA in the U.S., the collaboration seeks to address significant unmet needs in treatment variability. Exagen will market the resulting diagnostics under the AVISE® RADR brand.

Exagen Inc. (Nasdaq: XGN) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021. During this period, presentations will be available for registered attendees. On December 1, Exagen will hold one-on-one meetings, which can be requested exclusively through Piper Sandler. Key executives, including President Ron Rocca and CFO Kamal Adawi, will also host a virtual presentation that can be accessed via Exagen’s website. The company focuses on autoimmune testing solutions aimed at improving patient care.

Exagen Inc. (XGN) reported a 14% increase in quarterly revenue, reaching $12.3 million for Q3 2021. The AVISE® CTD test revenue surged by 34% to $9.9 million, driven by a 21% rise in testing volumes with 31,742 tests delivered. The company achieved a record of 1,969 ordering healthcare providers and maintained a 99% retention rate among adopters. However, operational expenses rose to $18.8 million, leading to a net loss of $7.2 million. Exagen reaffirmed its 2021 revenue guidance of $47-$49 million.

Exagen Inc. (Nasdaq: XGN) will participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18, 2021. Ron Rocca, President and CEO, and Kamal Adawi, CFO, will hold a virtual fireside chat at 10:30 AM ET. Interested viewers can access the live webcast from Exagen’s website. Exagen is focused on autoimmune testing solutions, aiming to enhance diagnosis and treatment for chronic autoimmune diseases such as rheumatoid arthritis and lupus through innovative testing products.